99.4% PURITY LOT VL-2972-A BPC-157 + TB-500 Blend
A 10 mg blend of BPC-157 and TB-500 supplied as a lyophilized vial for research into synergistic tissue repair and recovery.
A higher-strength 20 mg blend of BPC-157 and TB-500 supplied as a lyophilized vial for extended tissue-repair research.
- 1 × BPC-157 + TB-500 Blend 10mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
- 1 × BPC-157 + TB-500 Blend 20mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A 10 mg blend of BPC-157 and TB-500 supplied as a lyophilized vial for research into synergistic tissue repair and recovery.
- 10 mg total lyophilized blend per vial (5 mg + 5 mg)
- BPC-157 and TB-500 (Thymosin Beta-4 fragment)
- Synthetic peptide blend, ≥99% purity
- Studied for synergistic tissue repair
A higher-strength 20 mg blend of BPC-157 and TB-500 supplied as a lyophilized vial for extended tissue-repair research.
- 20 mg total lyophilized blend per vial (10 mg + 10 mg)
- BPC-157 and TB-500 (Thymosin Beta-4 fragment)
- Synthetic peptide blend, ≥99% purity
- Higher strength for extended research protocols
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Technical data
Current lot snapshot
Shipping
Reported use in research
BPC-157 and TB-500 (Thymosin Beta-4) are peptides studied for tissue repair through distinct but complementary mechanisms. BPC-157, a stable gastric pentadecapeptide, promotes angiogenesis and growth-factor regulation, while TB-500, a fragment of Thymosin Beta-4, supports cell migration, tissue regeneration, and reduced inflammation. Combined, they are investigated for synergistic effects on recovery.
Reported findings
The synergy is attributed to overlapping yet distinct pathways: BPC-157 improves blood flow and reduces inflammation while TB-500 facilitates cellular migration to the injury site. Early animal studies suggest the combination may shorten recovery times and improve the structural integrity of repaired tissues, though much of the evidence remains preclinical.
Handling & safety
Both peptides have shown favorable tolerability in animal research. Human clinical safety data are limited, and as a blend its combined profile remains largely preclinical and not fully characterized.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with Blend | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 9.99 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with Blend | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 9.98 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with Blend | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 9.99 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with Blend | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 20.08 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with Blend | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 19.92 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with Blend | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 20.08 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2972-A | Jul 2026 | 99.4% | TR-88626 | Active | |
| VL-2991-B | May 2026 | 99.5% | TR-88559 | Sold out | |
| VL-2610-C | Mar 2026 | 99.6% | TR-88568 | Sold out |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2927-A | Jul 2026 | 99.5% | TR-88799 | Sold out | |
| VL-2908-B | May 2026 | 99.4% | TR-88066 | Sold out | |
| VL-2965-C | Mar 2026 | 99.7% | TR-88093 | Sold out |
